Once a public health problem pegged for easy elimination, infectious diseases continue to be the leading cause of death worldwide. Despite improved methods of treating and preventing infection, including potent antibiotics, comprehensive immunization, and modern sanitation, infection still accounts for much serious illness, even in highly industrialized countries. Use this new Kalorama Information 3-volume series to evaluate your organization’s position in the highly active anti-infectives market.
Volume I Abstract
The World Market for Antifungal Medications
The market for pharmaceuticals targeted to treat human fungal infections is poised to experience strong growth over the next few years. This report from Kalorama Information provides details and insight into the current $4 billion worldwide market for anti-fungal treatments and the near 10% annual growth that will move the market in the near term.
Among the issues spurring growth is an aging population that is increasing the demand for medicines, including anti-fungal drugs, that will improve their lives as they grow older. In addition, the market is currently under-treated and underserved by existing anti-fungals, mainly in the amphotericin and a variety of azoles. Developing new successful and potent anti-fungal medications remains challenging, and the hunt has been underway for new therapeutics that will be able to improve efficacy, avoid multiple drug interactions, and offer an improved safety profile. Many drugs on the verge of the commercial market purport to achieve of these objectives. Optimizing their mode of delivery will help optimize their activity and reduce costs for the developer.
This report offers an overview of the world anti-fungal market, including insight into the anti-fungal activities of the major players such as Pfizer, Johnson & Johnson, Merck, Novartis, and others. It also examines the efforts of smaller companies that are developing their own niches, and which may be the source for many more effective anti-fungal therapies. The report forecasts the world market for anti-fungal therapies through 2006 and offers details on specific segments of the market. In addition, the report examines patent and exclusivity expiration timing and issues for many key anti-fungal pharmaceuticals.
Volume II Abstract
The World Market for Antibacterial Medications
Antibiotic development has never proceeded at this pace or with this much urgency. Demand for effective antibacterial compounds is growing rapidly and companies are trying to fill their pipelines with products that can meet the challenges of increasingly stubborn infectious agents. By far the largest of the anti-infective segments, antibacterials represent approximately 65% of the $20 billion world market in infectious disease drugs. However, it’s also the most crowded of the segments with big pharma and small biotech companies alike speeding toward the market. The second volume of Kalorama’s ongoing market study on anti-infectives tackles this large and dynamic segment with a global report on the clinical, regulatory, business, and even political forces that are shaping the rapidly changing antibiotic market.
Volume III Abstract
The World Market for Antiviral Medications
This report analyzes the world markets for human antiviral medications, focusing on the current market for and the development of drugs that are used to directly combat and treat viruses viral infections. For the purposes of this report, antivirals are drugs used to directly treat viral infection after it occurs. The report does not discuss products for the prevention of viral infection—that is, adult or pediatric vaccinations—and does not discuss other diseases, such as cancer or heart disease, that may be caused by a virus.
Market analysis is provided for various geographic regions and for various viral groups to 2006. The report profiles several companies involved in marketing or developing antiviral products, including Boehrinnger Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Pfizer, and Merck, among others. The report generally reviews the nature and direction of research, as well as the markets for currently available drugs.
Market forecasts are based on an examination of current market conditions and on investigations into the development of new products by key companies. This information also is weighted with projected timing and the probability of receiving FDA approval to market products. The information presented in this report is the result of data gathered from interviews with company executives and other industry stakeholders. Company product literature and other corporate brochures and documents, as well as information found in the scientific and trade press, provide supporting information. BR>
Volumes in this series may also be purchased separately. Individual chapters of each volume are also available via our Buy by the Slice feature.
Volume I: The World Market for Antifungal Medications
Volume II: The World Market for Antibacterial Medications
Volume III: The World Market for Antiviral Medications